What is King-Devick Test?
King-Devick Technologies, Inc. operates at the intersection of neurology and digital health, providing sophisticated tools for the assessment and monitoring of eye movement disorders. The company is best known for its flagship King-Devick Test, a rapid screening instrument utilized extensively in concussion management protocols to identify neurological impairments. Beyond clinical diagnostics, the firm has expanded its footprint into the educational sector with the King-Devick Reading Acceleration Program. This dual-market approach allows the company to serve a diverse clientele, ranging from professional sports organizations and healthcare providers to academic institutions seeking evidence-based solutions for reading fluency and cognitive performance enhancement.
How much funding has King-Devick Test raised?
King-Devick Test has raised a total of $399K across 2 funding rounds:
Debt
$150K
Debt
$249K
Debt (2020): $150K with participation from PPP
Debt (2021): $249K led by PPP
Key Investors in King-Devick Test
PPP
Public-Private Partnership
What's next for King-Devick Test?
With this late-stage financing secured, King-Devick Test is poised to transition into a phase of aggressive market expansion and product refinement. The strategic deployment of these funds will likely focus on enhancing the digital infrastructure of their diagnostic platforms and broadening the clinical validation of their reading intervention tools. As the demand for objective, data-driven neurological monitoring continues to rise, the company is strategically aligned to capture additional market share. Future growth will likely be driven by the integration of their proprietary assessment technology into broader telehealth ecosystems and the continued adoption of their reading acceleration programs within global educational frameworks, ensuring sustained long-term value creation.
See full King-Devick Test company page
